Scientific Sessions 2024  /  GLP-1RAs and Beyond: Incretin Analogues and a New Frontier in Cardiovascular Therapeutics  /  Panel Discussion
Logo

American Heart Association

  2
  0

Final ID:

Panel Discussion

  • Jastreboff, Ania  ( Yale School of Medicine , New Haven , Connecticut , United States )
    • Author Disclosures:
    Ania Jastreboff: DO have relevant financial relationships ; Researcher:Eli Lilly:Active (exists now) ; Advisor:Regeneron:Active (exists now) ; Individual Stocks/Stock Options:Intellihealth:Active (exists now) ; Advisor:Scholar Rock:Active (exists now) ; Advisor:Structure Therapeutics:Active (exists now) ; Advisor:Zealand:Active (exists now) ; Advisor:Weight Watchers:Active (exists now) ; Advisor:Pfizer, Terns Pharmaceuticals:Active (exists now) ; Advisor:Novo Nordisk:Active (exists now) ; Advisor:Eli Lilly:Active (exists now) ; Advisor:Boehringer Ingelheim, Biohaven:Active (exists now) ; Advisor:Amgen, AstraZeneca:Active (exists now) ; Researcher:Rhythm Pharmaceuticals:Active (exists now) ; Researcher:Boehringer Ingelheim:Active (exists now) ; Researcher:Novo Nordisk:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

GLP-1RAs and Beyond: Incretin Analogues and a New Frontier in Cardiovascular Therapeutics

Sunday, 11/17/2024 , 09:45AM - 11:00AM

Main Event

More abstracts on this topic:
How do we SELECT incretin analogues and SUSTAIN their impact? Clinical approaches for short and long-term obesity care

Jastreboff Ania, Lingvay Ildiko

Going with the FLOW: Understanding the renal effects of GLP-1RA therapy

Tuttle Katherine, Rangaswami Janani

More abstracts from these authors:
Managing Obesity and MASLD - Whose Job Is It?

Jastreboff Ania, Woodhouse Sheila, Mehta Anurag

How do we SELECT incretin analogues and SUSTAIN their impact? Clinical approaches for short and long-term obesity care

Jastreboff Ania, Lingvay Ildiko

You have to be authorized to contact abstract author. Please, Login
Not Available